Dengue Fever,  COVID ‐19 ( SARS‐CoV ‐2), and  Antibody‐Dependent  Enhancement ( ADE ): A Perspective | Zendy

Ulrich Henning | Zendy; Pillat Micheli M. | Zendy; Tárnok Attila | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Dengue Fever, COVID ‐19 ( SARS‐CoV ‐2), and Antibody‐Dependent Enhancement ( ADE ): A Perspective

Author(s) -

Ulrich Henning,

Pillat Micheli M.,

Tárnok Attila

Publication year - 2020

Publication title -

cytometry part a

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.316

H-Index - 90

eISSN - 1552-4930

pISSN - 1552-4922

DOI - 10.1002/cyto.a.24047

Subject(s) - dengue fever , dengue virus , antibody , virology , antibody dependent enhancement , covid-19 , virus , coronavirus , immunology , pandemic , biology , medicine , microbiology and biotechnology , infectious disease (medical specialty) , disease , pathology

SARS‐CoV‐2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus‐caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody‐dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fcγ receptor‐mediated virus uptake. No clinical data exist indicating such mechanism for SARS‐CoV‐2, but previous coronavirus infections or infection of SARS‐CoV‐2 convalescent with different SARS‐CoV‐2 strains could promote ADE, as experimentally shown for antibodies against the MERS‐CoV or SARS‐CoV spike S protein. © 2020 International Society for Advancement of Cytometry

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research